The Chronic Obstructive Pulmonary Disease (COPD) market has been forecast to reach an industry value of $15.6 billion by 2019, increasing from a total of $11.3 billion at the beginning of 2013.
According to a latest report, 'Chronic Obstructive Pulmonary Disease (COPD) Market to 2019,' the UK will witness an increase in COPD in the near future, with the corresponding therapy market demonstrating greater revenue growth as a result.
COPD prevalence in the UK will climb from 2.3 million in 2012 to 2.8 million in 2019, while other major European countries, including Germany, France, Italy and Spain, are anticipated to experience relatively stable patient figures.
COPD is the fifth-leading cause of death in the world and is the occurrence of chronic bronchitis or emphysema, a pair of commonly co-existing diseases of the lungs in which the airways narrow over time. This limits airflow to and from the lungs, causing shortness of breath.
COPD is caused primarily by tobacco smoke, with a number of other factors playing a less common role. This triggers an inflammatory response in the lung. Management involves quiting smoking, vaccinations, rehabilitation, and often inhaled bronchodilators. Some people require long-term oxygen therapy or lung transplantation.
The UK's steadily rising COPD prevalence could be attributed to greater awareness and diagnosis of COPD amongst younger people. The early stages of COPD often go undiagnosed, resulting in low diagnosis rates, but this is expected to improve across the UK in the following decade.
The global COPD therapeutics market will be driven by the entry of new, more efficacious and convenient products over the coming years.
Some pharma manufacturers were set to see sales from their key brands in the area decline as patent expiries bite. GlaxoSmithKline (GSK) was hit by generic competition for Seretide (fluticasone propionate), while Merck & Co saw huge losses following the FDA's approval of first generic version of its asthma drug Singulair in July 2012. The drug made $4.4 billion during 2011.
Upcoming combination drugs including Novartis's QVA-149, GSK's umeclidinium bromide/vilanterol and Boehringer Ingelheim's olodaterol/tiotropium promise greater efficacy than their individual components and currently available treatments, and the continued growth of the industry will rely largely on their success.
For more information on the COPD market, see the latest research: Chronic Obstructive Pulmonary Disease Market Research
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.